Near Infrared Imaging Market




While exciting, the dynamics here are still at the early stage with awesome promises as a new point-of-care medical imaging modality that can potentially provide the sensitivity of nuclear medicine techniques.
 
For those who are unfamiliar, near infrared imaging is billed as a powerful diagnostic technique with potential to serve as a minimally invasive, non-ionizing method for sensitive, deep tissue diagnostic imaging. Based on product type, the global market is segmented into near-infrared fluorescence imaging, near infrared fluorescence & bioluminescence imaging devices, and reagents.
According to Research and Markets, the global near-infrared imaging market is projected to reach USD 471.2 million by 2020, at a CAGR of 8.8% from 2015 to 2020.

By application, the near-infrared imaging market has been segmented into in vivo imaging, cancer surgeries, cardiovascular surgeries, gastrointestinal surgeries, plastic/reconstructive surgeries, and others. The end users of near-infrared imaging devices are hospitals and research labs. 

Research and Markets reveals that, North America contributed the largest share to the near-infrared imaging market in 2014. The large share is attributed to increasing cancer cases, increasing technological advancements, and advantages offered by near-infrared imaging devices over other imaging methods. 

The global near infrared imaging market is projected to reach USD 471.2 Million by 2020, at a CAGR of 8.8% from 2015 to 2020. Europe emerges as a fastest-growing market for near infrared imaging.

The major players operating in this market are Biospace Lab (France), Fluoptics (France), Mizuho Corporation (Japan), Li-Cor, Inc. (U.S.), Bruker Corporation (U.S.), Carl Zeiss Meditec AG (Germany), Novadaq Technologies Inc. (Canada), Hamamatsu Photonics K.K. (Japan), Karl Storz GmbH & Co. KG (Germany), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.), and Miltenyi Biotech (Germany).